Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Thyroid Carcinoma, Anaplastic × Adalimumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Endocrine 1

Conditions

Uveal Melanoma 1 Thyroid Carcinoma, Anaplastic 1 Melanoma 1 Healthy Adult Male 1 Healthy 1

Interventions

dabrafenib 2 Trastuzumab 2 vandetanib 1 tumor necrosis factor-alpha, CNGRC fusion protein, human 1 tremelimumab 1 trametinib 1 tipifarnib 1 mercaptoundecahydrododecaborate 1 durvalumab 1 cemiplimab 1 Semaxinib 1 Radiotherapy, Intensity-Modulated 1 Radiosurgery 1 Paclitaxel 1 PLX8394 1 Interleukin-12 Subunit p35 1 Interleukin-12 1 Docetaxel 1 Adalimumab 1 4-boronophenylalanine-fructose 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02516774 2016-01-26

TAM-RT

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1 Withdrawn

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡